CN110483470B - 一种制备盐酸兰地洛尔的方法 - Google Patents
一种制备盐酸兰地洛尔的方法 Download PDFInfo
- Publication number
- CN110483470B CN110483470B CN201910781070.8A CN201910781070A CN110483470B CN 110483470 B CN110483470 B CN 110483470B CN 201910781070 A CN201910781070 A CN 201910781070A CN 110483470 B CN110483470 B CN 110483470B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- preparing
- landiolol hydrochloride
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C263/00—Preparation of derivatives of isocyanic acid
- C07C263/16—Preparation of derivatives of isocyanic acid by reactions not involving the formation of isocyanate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C265/00—Derivatives of isocyanic acid
- C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
- C07C265/04—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
- C07C273/1818—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety from -N=C=O and XNR'R"
- C07C273/1827—X being H
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
本发明属于医药化工领域,更为具体地说是涉及一种制备兰地洛尔及式8化合物的改良方法。即由通式7化合物与AH(有机胺)反应制得式8化合物。本发明还涉及通式7化合物。
Description
技术领域
本发明具体的涉及一种制备盐酸兰地洛尔的方法。
背景技术
盐酸兰地洛尔(Landiolol hydrochloride)为选择性β1-受体阻断剂,主要拮抗存在于心脏的β1-受体,通过抑制由儿茶酚胺引起的心博数增加,改善心动过速性心律失常。动物实验表明其β1-受体阻断活性是艾司洛尔(Esmolol)的9倍,其心脏选择性是艾司洛尔的8倍。该药于2002年由小野制药在日本首次上市,用于手术时心律失常的紧急处置。其半衰期极短、起效快,若出现副作用,减少或停药之后副作用可快速解除。
盐酸兰地洛尔
文献(Chem.Pharm.Bull.1992,40(6):1462-1469;特开平05-306281(JP);EP0397031;CN101012217A)报道了几种制备盐酸兰地洛尔的方法,均为化合物6a与化合物9反应。
然而化合物10制备比较繁琐,后处理困难,而且大都使用毒性较大的氯甲酸苯酯或者羰基二咪唑。
本发明描述了一种制备盐酸兰地洛尔及其类似化合物的改良方法。通过改用新的物料,明显更为有效地合成了盐酸兰地洛尔。
发明内容
本发明公开了一种制备式8化合物的方法:
化合物6参照文献(Chem.Pharm.Bull.1992,40(6):1462-1469;特开平05-306281(JP);EP0397031;CN101012217A)方法制备。
化合物3通常是以其盐的形式存在,参照通用方法如下式制备:
其中:R1基团表示C1-C6取代的烷氧基、优选甲氧基、A基团表示C1~6取代的伯氨基、C1~6取代的仲氨基、C2-5的环氨基、C2-4的环杂氨基、取代或未取代的芳氨基,优选异丙氨基、叔丁氨基、哌啶基、吗啉基。
步骤1:
将式6化合物与化合物3(优选盐酸盐、三氟乙酸盐)在选自甲苯、四氢呋喃、2-甲基四氢呋喃、环己烷、1,4-二氧六环、乙腈、二氯甲烷和三氯甲烷的溶剂(优选四氢呋喃、乙腈)中,加入有机叔胺(优选三乙胺、二异丙基乙胺)或无机碱(优选碳酸氢钠、碳酸氢钾、碳酸钠、碳酸钾)进行反应,反应温度为-10~100℃,优选10~30℃。
反应结束,加入溶剂(优选乙酸乙酯、乙酸异丙酯、二氯甲烷),用纯化水洗涤,收集有机层,浓缩,再加入溶剂(优选乙醚、异丙醚、甲基叔丁基醚、石油醚、正己烷、正庚烷)搅拌,固液分离,干燥,得到式7化合物。
步骤2:
将式7化合物与有机胺(AH)在无溶剂或在不与式7化合物反应的溶剂(优选甲苯、四氢呋喃、2-甲基四氢呋喃、环己烷、1,4-二氧六环、乙腈、二氯甲烷、三氯甲烷,更优选四氢呋喃、乙腈)中进行,反应温度为-10~100℃,优选10~40℃。
反应结束后加入溶剂(优选乙酸乙酯、乙酸异丙酯、二氯甲烷),用纯化水、饱和氯化钠水溶液洗涤,收集有机层,浓缩得到式8化合物。
步骤3:
式8化合物可在步骤3中转化为盐酸盐,类似现有技术将8与HCl反应。
本发明另一方面涉及上述方法的新的中间体产物。其包括式7化合物:
使用式7化合物用于研究制备符合药学用途的盐酸兰地洛尔及其药物组合物。
具体实施方式
实施例
实施例1
①式7a化合物的制备
将化合物6a(10g,29.73mmol)、化合物3的盐酸盐(5.46g,44.59mmol)、加入到乙腈(20mL)中,再加入三乙胺(4.51g,44.59mmol),加毕,于10~30℃反应15~20h,反应结束,加入二氯甲烷(100mL),用纯化水(100mL×3)洗涤,无水硫酸钠干燥,过滤,滤液25℃以下减压浓缩至干,残留物加入甲基叔丁基醚(100mL),室温搅拌1h,析出大量白色固体。过滤,甲基叔丁基醚洗涤,25℃以下真空干燥,得到10.68g化合物7a,收率85.0%。HPLC纯度99.4%。
1H-NMR(DMSO-d6,500MHz,ppm)δ:1.36(s,3H,-CH3)、1.42(s,3H,-CH3)、2.62(t,J=7.5Hz,2H,-CH2-)、2.89(t,J=7.4Hz,2H,-CH2-)、3.38(m,2H,-CH2-)、3.44(t,J=7.7Hz,2H,-CH2-)、3.54(m,2H,-CH2-)、3.68(t,J=7.1Hz,1H,CH2)、3.8~4.4(br,1H,-OH)、3.93(t,J=7.6Hz,1H,-CH2-)、3.97(t,J=7.5Hz,1H,-CH2-)、4.03(t,J=7.4Hz,1H,-CH2-)、4.08(m,1H,-CH2-)、4.13(m,1H,-CH2-)、4.15(m,1H,-CH-)、4.27(m,1H,-CH-)、4.8~5.8(br,1H,-NH)、6.83(d,J=8.1Hz,2H,Ph-H)、7.10(d,J=8.1Hz,2H,Ph-H)。13C NMR(DMSO-d6,δ):25.330(CH3)、26.629(CH3)、29.957(CH2)、35.837(CH2)、38.724(CH2)、47.382(CH2)、47.765(CH2)、64.655(CH2)、66.281(CH2)、69.365(CH2)、69.365(CH)、73.532(CH)、109.756(C)、114.580(CH)、129.265(CH)、132.898(CH)、157.013(CH)、164.178(CH)、172.589(CH)。
HR-MS Calcd for C16H19N3O5:422.2053,Found:422.2059。
②式7a化合物的制备
将化合物6a(10g,29.73mmol)、化合物3的三氟乙酸盐(8.92g,44.59mmol)、加入到乙腈(20mL)中,再加入三乙胺(4.51g,44.59mmol),加毕,于10~30℃反应15~20h,反应结束,加入二氯甲烷(100mL),用纯化水(100mL×3)洗涤,无水硫酸钠干燥,过滤,滤液25℃以下减压浓缩至干,残留物加入甲基叔丁基醚(100mL),室温搅拌1h,析出大量白色固体。过滤,甲基叔丁基醚洗涤,25℃以下真空干燥,得到10.83g化合物7a,收率86.2%。
③将化合物6a(1g,2.973mmol)、化合物3的三氟乙酸盐(0.89g,4.459mmol)、加入到四氢呋喃(2mL)中,再加入三乙胺(0.45g,4.459mmol),加毕,于10~30℃反应15~20h,反应结束,加入二氯甲烷(10mL),用纯化水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液25℃以下减压浓缩至干,残留物加入甲基叔丁基醚(10mL),室温搅拌1h,析出大量白色固体。过滤,甲基叔丁基醚洗涤,25℃以下真空干燥,得到1.03g化合物7a,收率82.0%。
④式8a化合物的制备
将化合物7a(10g,23.67mmol)、吗啉(3.10g,35.5mmol)、二氯甲烷(50mL)加入到反应瓶中,于15~25℃反应15~20h,反应结束,用纯化水(100mL×3)洗涤,饱和氯化钠水溶液(100mL×3)洗涤,无水硫酸钠干燥,过滤,滤液于35℃以下减压浓缩至干,得到11.81g化合物8a,收率97.9%,HPLC纯度99.6%。
⑤式8a化合物的制备
将化合物7a(10g,23.67mmol)、吗啉(3.10g,35.5mmol)、乙腈(10mL)加入到反应瓶中,于15~25℃反应15~20h,反应结束,加入二氯甲烷(100mL),用纯化水(100mL×3)洗涤,饱和氯化钠水溶液(100mL×3)洗涤,无水硫酸钠干燥,过滤,滤液于35℃以下减压浓缩至干,得到11.92g化合物8a,收率98.8%。
⑥盐酸兰地洛尔的制备
将兰地洛尔(10g,19.62mmol)、乙酸乙酯100mL加入到反应瓶中,冰水浴降温至5℃以下,控温10℃以下滴加15~18%的HCl-乙酸乙酯溶液4.63g,逐渐有大量固体析出,滴毕,10℃以下搅拌2h,过滤,乙酸乙酯洗涤,50℃真空干燥得白色固体10.28g,收率95.9%,HPLC纯度99.85%。
实施例2
①式7b化合物的制备
同实施例1化合物7a的制备,投入化合物6b(10g,42.32mmol),得到11.88g化合物7b,收率87.1%。HR-MS Calcd for C16H22N2O5:322.1529,Found:322.1522。
②式8b化合物的制备
同实施例1化合物8a的制备,投入化合物7b(10g,31.02mmol),得到12.17g化合物8b,收率95.8%。HR-MS Calcd for C20H31N3O6:409.2213,Found:409.2215。
实施例3
式8c化合物的制备
同实施例1化合物8a的制备,投入化合物7b(10g,31.02mmol),得到11.12g化合物8c,收率94.0%。HR-MS Calcd for C19H31N3O5:381.2264,Found:381.2260。
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910781070.8A CN110483470B (zh) | 2019-08-21 | 2019-08-21 | 一种制备盐酸兰地洛尔的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910781070.8A CN110483470B (zh) | 2019-08-21 | 2019-08-21 | 一种制备盐酸兰地洛尔的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110483470A CN110483470A (zh) | 2019-11-22 |
CN110483470B true CN110483470B (zh) | 2022-09-30 |
Family
ID=68551753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910781070.8A Active CN110483470B (zh) | 2019-08-21 | 2019-08-21 | 一种制备盐酸兰地洛尔的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110483470B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05306281A (ja) * | 1992-04-24 | 1993-11-19 | Ono Pharmaceut Co Ltd | フェニルアルカン酸エステルの塩酸塩およびその中間体の新規な製造方法 |
CN101012217A (zh) * | 2007-02-08 | 2007-08-08 | 北京化工大学 | 一种盐酸兰地洛尔的合成方法 |
JP2012184229A (ja) * | 2011-03-04 | 2012-09-27 | Procos Spa | ランジオロールのエナンチオ選択的合成のためのプロセス |
EP2687521A1 (en) * | 2012-07-20 | 2014-01-22 | Procos S.p.A. | "Process for the enantioselective synthesis of landiolol" |
CN106608863A (zh) * | 2015-10-23 | 2017-05-03 | 北京创立科创医药技术开发有限公司 | 一种盐酸兰地洛尔的制备方法 |
CN108752308A (zh) * | 2018-08-06 | 2018-11-06 | 江苏恒瑞医药股份有限公司 | 一种盐酸兰地洛尔的制备方法 |
-
2019
- 2019-08-21 CN CN201910781070.8A patent/CN110483470B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05306281A (ja) * | 1992-04-24 | 1993-11-19 | Ono Pharmaceut Co Ltd | フェニルアルカン酸エステルの塩酸塩およびその中間体の新規な製造方法 |
CN101012217A (zh) * | 2007-02-08 | 2007-08-08 | 北京化工大学 | 一种盐酸兰地洛尔的合成方法 |
JP2012184229A (ja) * | 2011-03-04 | 2012-09-27 | Procos Spa | ランジオロールのエナンチオ選択的合成のためのプロセス |
EP2687521A1 (en) * | 2012-07-20 | 2014-01-22 | Procos S.p.A. | "Process for the enantioselective synthesis of landiolol" |
CN106608863A (zh) * | 2015-10-23 | 2017-05-03 | 北京创立科创医药技术开发有限公司 | 一种盐酸兰地洛尔的制备方法 |
CN108752308A (zh) * | 2018-08-06 | 2018-11-06 | 江苏恒瑞医药股份有限公司 | 一种盐酸兰地洛尔的制备方法 |
Non-Patent Citations (3)
Title |
---|
Development of a Highly Cardioselective Ultra Short-Acting β-Blocker,ONO-1101;Sadahiko IGUCHI等;《Pharmaceutical Society of Japan》;19921231;第40卷(第6期);1462-1469 * |
Structural analysis of an impurity of the drug landiolol;Michal Š tujber等;《MRC letters》;20140116;第52卷(第3期);122-127 * |
一种含有双药效团的兰地洛尔类似物的合成及表征;张隽 等;《中国药物化学杂志》;20051020;第15卷(第5期);274-276 * |
Also Published As
Publication number | Publication date |
---|---|
CN110483470A (zh) | 2019-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU707075B2 (en) | Carbocyclic intermediates and process of manufacture thereof | |
EP0529842B1 (en) | Production of fluoxetine and new intermediates | |
JP4597237B2 (ja) | 置換シクロペンタン誘導体の調製方法及びその新規結晶構造 | |
KR20120083416A (ko) | 아자비시클릭 화합물의 제조 방법 | |
WO2012168364A1 (en) | Apixaban preparation process | |
JP2008525486A (ja) | 置換ピペリジンの製造方法 | |
KR20060126965A (ko) | 활성 아민기 존재하에서 o-카바모일 화합물을 제조하는방법 | |
EP2611776B1 (en) | Production method of intermediate compound for synthesizing medicament | |
KR19990036165A (ko) | 2-옥사졸리디논 유도체의 단일 포트 합성 | |
US6040446A (en) | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | |
KR20190044652A (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
CN110483470B (zh) | 一种制备盐酸兰地洛尔的方法 | |
WO2021214502A1 (en) | Process for preparing a phthalazinone derivative and intermediates thereof | |
JPH02306947A (ja) | キラルβ―アミノ酸の製造方法 | |
CZ299193B6 (cs) | Zpusob výroby inhibitoru HIV proteázy | |
KR100519691B1 (ko) | 알킬옥시 퓨라논 유도체의 제조방법, 상기 방법으로 얻은화합물 및 상기 화합물의 용도 | |
EP3807268A1 (en) | Process for the preparation of lifitegrast | |
EP1926709A1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
JP3204368B2 (ja) | 光学活性アミド類の製法 | |
CN114736186B (zh) | 一种由氨基甲酸叔丁酯合成维兰特罗中间体的方法 | |
JP4956614B2 (ja) | 3−アミノ−5−フルオロ−4−ジアルコキシペンタン酸エステルを製造する新規な方法 | |
KR20020015031A (ko) | 3-아미노-3-아릴 프로파노에이트의 합성 | |
US6150417A (en) | Phenoxyethylamine derivatives, method of preparation application as medicine and pharmaceutical compositions containing same | |
JPH0637449B2 (ja) | 光学活性アテノロール及びその中間体の製法 | |
KR100242857B1 (ko) | 비시클릭 아민의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |